Valproate add-on therapy for drug-resistant focal epilepsy (original) (raw)

Short-term efficacy and safety of valproate sustained-release formulation in newly diagnosed partial epilepsy VIPe-study. A multicenter observational open-label study

Hassan Al Hail

Saudi medical journal, 2007

View PDFchevron_right

IV Valproate in generalized convulsive status epilepticus: a systematic review

Luigi Bongiovanni, Francesco Brigo

European Journal of Neurology, 2012

View PDFchevron_right

Conventional and sustained-release valproate in children with newly diagnosed epilepsy: a randomized and crossover study comparing clinical effects, patient preference and pharmacokinetics

Rosa Arteaga, Javier Adín

European Journal of Clinical Pharmacology, 2006

View PDFchevron_right

Efficacy and safety of intravenous valproate for status epilepticus: a systematic review

Francesco Brigo

2014

View PDFchevron_right

Short-term efficacy and safety of valproate sustained-release formulation in newly diagnosed partial epilepsy (VIPe-study)

Boulenouar Mesraoua

2007

View PDFchevron_right

Efficacy of Valproate in Partial Epilepsy and Patient Compliance and Satisfaction with Long Acting Valproate Form

Seher Naz

journalagent.com

View PDFchevron_right

Comparison of short-term efficacy of valproate sustained-release between adult and children as first-line monotherapy in management of partial epilepsy: A multicenter observational open-label study

Mohiuddin Sikder

Journal of National Institute of Neurosciences Bangladesh, 2015

View PDFchevron_right

Valproate in children with newly diagnosed idiopathic generalized epilepsy

George Vartzelis

Acta Neurologica Scandinavica, 2010

View PDFchevron_right

Valproate is an effective, well-tolerated drug for treatment of status epilepticus/serial attacks in adults

Leif Gjerstad

Acta Neurologica Scandinavica, 2007

View PDFchevron_right

Assessment of the reporting quality of RCTs for sodium valproate in status epilepticus pupublished from 2007 to 2018 based on the CONSORT statement

Ιωάννης ΛιΆμπας

2020

View PDFchevron_right

Compliance and satisfaction with switching from an immediate-release to sustained-release formulation of valproate in people with epilepsy

Gus Baker

Epilepsy & Behavior, 2003

View PDFchevron_right

A comparative study of progabide, valproate, and placebo as add-on therapy in patients with refractory epilepsy

Patricia Crawford

Journal of Neurology, Neurosurgery & Psychiatry, 1986

View PDFchevron_right

Accuracy of Calculated Free Valproate Levels in Adult Patients With Status Epilepticus

Stephan Rueegg

Neurology, 2020

View PDFchevron_right

Valproate-induced Parkinsonism in epilepsy patients

Danrick Jamora

Movement disorders : official journal of the Movement Disorder Society, 2007

View PDFchevron_right

Valproate in the treatment of epilepsy in women and girls Recommendations from a joint Task Force of ILAE-Commission on European Affairs and European Academy of Neurology (EAN)

Maria Paola Canevini

Epilepsia, 2015

View PDFchevron_right

Prospective Observational Study of Sodium Valproate in Seizure Control and Associated Adverse Drug Reactions in Pediatric Population

nagesh adla

2015

View PDFchevron_right

Antiepileptic drug add-on therapy for focal epilepsy: a network meta-analysis

Myrsini Gianatsi

Cochrane Database of Systematic Reviews, 2021

View PDFchevron_right

Conventional and controlled release valproate in children with epilepsy: a cross-over study comparing plasma levels and cognitive performances

T. Stijnen

Epilepsy Research, 1992

View PDFchevron_right

Reduction of Steady-State Valproate Levels by Other Antiepileptic Drugs

J. Chris Sackellares

Epilepsia, 1981

View PDFchevron_right

Common reference-based indirect comparison meta-analysis of intravenous valproate versus intravenous phenobarbitone in generalized convulsive status epilepticus

Luigi Bongiovanni, Frediano Tezzon, Stanley Igwe, Francesco Brigo

Journal of the Neurological Sciences, 2013

View PDFchevron_right

Low-dose sodium valproate in the treatment of idiopathic generalized epilepsies

J. Salas-Puig

Acta Neurologica Scandinavica, 2013

View PDFchevron_right

The Frequency of Reversible Parkinsonism and Cognitive Decline Associated with Valproate Treatment: A Study of 364 Patients with Different Types of Epilepsy

Nikola Vojvodic

Epilepsia, 2006

View PDFchevron_right

The tolerability and safety of valproate sodium injection given as an intravenous infusion

R Eugene Ramsay

Journal of Epilepsy, 1997

View PDFchevron_right

Role of valproate across the ages. Treatment of epilepsy in the elderly

Bettina Schmitz

Acta Neurologica Scandinavica, 2006

View PDFchevron_right

New valproate regulations, informed choice and seizure risk

heather angus-leppan

Journal of neurology, 2024

View PDFchevron_right

Conversion from delayed-release sodium valproate to extended-release sodium valproate: Initial results and long-term follow-up

Erik Lehman

Epilepsy & Behavior, 2006

View PDFchevron_right

Valproic Acid as Adjuvant Treatment for Convulsive Status Epilepticus: a Randomised Clinical Trial

Christine Lebert

View PDFchevron_right

Use of intravenous valproate in three pediatric patients with nonconvulsive or convulsive status epilepticus

James Dalton

Annals of Pharmacotherapy, 1999

View PDFchevron_right

Comparative bioavailaibilty of two valproic acid delayed-release tablets in healthy volunteers with tighter acceptance criteria to anticipate breakthrough seizures

Yahdiana Harahap

Pharmaceutical Sciences Asia

View PDFchevron_right

Disposition of sodium valproate in epileptic patients

Stefano Calzetti

British Journal of Clinical Pharmacology, 1978

View PDFchevron_right

Safety of intravenous valproate

John Pellock

Annals of Neurology, 1995

View PDFchevron_right

The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial

Paola Nicolaides

The Lancet, 2007

View PDFchevron_right